Anna Sureda, MD, PhD, is the EBMT President, Head of the Clinical Hematology Department and Hematopoietic Stem Cell Transplant Programme at Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain and Associate Professor of the University of Barcelona.

Selim Corbacioglu is the former Pediatric Diseases Working Party (PDWP) Chair and EBMT Scientific Council Chair, Professor and Chair of the Department of Hematology, Oncology and Stem Cell Transplantation at the Children's Hospital in Regensburg, Germany.

Raffaella Greco, MD, is the current Autoimmune Diseases Working Party (ADWP) Chair and EBMT Scientific Council Representative with the Education Portfolio, and Senior Physician in the Blood and Marrow Transplant (BMT) Unit of the IRCCS San Raffaele Hospital in Milano, Italy

Nicolaus Kröger, MD, PhD, is the former EBMT President, Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany.

Enric Carreras, MD, PhD, Medical Advisor of the Josep Carreras Foundation in Barcelona, Spain. EBMT Honorary member.

Part I . Introduction.- 1. HCT: Historical Perspective.- 2. The EBMT: History, Present, and Future.- 3. Registries - a bridge between donor and recipient.- 4. The HCT Unit.- 5. JACIE Accreditation of HCT Programs.- 6. Statistical Methods in HCT and Cellular Therapies.- Part II . Biological Aspects.- 7. Biological Properties Of Hematopoietic Stem Cells: Scientific Basis For Hematopoietic Cell Transplantation.- 8. Biological Properties of Cells Other Than HSCs.- 9. Histocompatibility.- 10. Clinical and biological concepts for mastering immune reconstitution after hematopoietic cell transplantation: towards practical guidelines and greater harmonization.- Part III . Methodology and Clinical Aspects.- 11. Evaluation and Counseling of Candidates.- 12. Donor Selection for Adults and Pediatrics.- 13. Conditioning.- 14. Selection of stem cell source.- 15. Bone Marrow Harvesting for HCT.- 16. Mobilization and Collection of HSC.- 17. Mobilization and Collection of HSC in Children.- 18. Procurement and Management of Cord Blood Unit for allogeneic transplantation.- 19. Graft Manipulation.- 20. Processing, Cryopreserving and Controlling the Quality of HSC.- 21. Documentation of Engraftment and Chimerism After HCT.- 22. Short- and Long-Term Controls After HCT.- Part IV . General Management of the Patient.- 23. Vascular Access.- 24. Transfusion Support.- 25. Nutritional Support.- 26. GVHD Prophylaxis.- 27. Infection Control and Isolation Procedures.- 28. General Management of the Patient: Specific Aspects of Infectious Disease Supportive Care in Children.- 29. Vaccinations.- 30. Psychological Morbidity and Care.- 31. Clinically Relevant Drug Interactions in HCT.- 32. The Roles of the HCT Nurse.- 33. Ethical Issues in HCT.- 34. Quality of Life Assessment After HCT for Pediatric and Adults.- Part V. HCT Complications and Management.- 35. Neutropenic Fever.- 36. Bacterial Infections.- 37. Invasive fungal diseases.- 38. Viral Infections.- 39. Other Life-Threatening Infections.- 40. Bleeding and Thrombotic Complications.- 41. Graft Failure.- 42. Early complications of endothelial origin.- 43. Acute Graft-Versus-Host Disease.- 44. Chronic Graft-Versus-Host Disease.- 45. Post-transplant lymphoproliferative syndromes.- 46. Iron Overload.- 47. Secondary Neoplasia (Other than PTLPS).- Part VI . Specific Organ Complications.- 48. Ocular and Oral Complications .- 49. Hepatic complications.- 50. Gastrointestinal Complications.- 51. Haemorrhagic Cystitis and Renal Dysfunction.- 52. Noninfectious Pulmonary Complications.- 53. Neurological Complications.- 54. Skin, Hair and Musculoskeletal Complications.- 55. Cardiovascular Diseases and Metabolic Syndrome.- 56. Endocrine Disorders, Fertility and Sexual Health.- Part VII . Prevention and Management of Relapse.- 57. Monitoring Measurable Residual Disease in ALL and AML.- 58. Prevention and Treatment of Relapse by Drugs.- 59. Delayed transfer of immune cells, or the art of donor lymphocyte infusion (DLI) 2.0.- 60. Cellular Therapy with Engineered T Cells, Efficacy and Side Effects: Gene Editing/Gene Therapy.- 61. Mechanisms of Immune Resistance.- 62. Regulatory Aspects Of Atmp Versus Minimally Manipulated Immune Cells.- Part VIII . Specific Modalities of HCT and Management.- 63. At Home HCT.- 64. Role Of Umbilical Cord Blood Transplantation.- 65. Haploidentical HCT.- 66. Photopheresis in Adults and Pediatrics.- 67. Overweight and obese patients.- 68. HCT in Elderly Patients.- 69. Feasibility and Experiences of HCT in Resource-constrained Settings.- Part IX . Indications and Results.- 70. AML in adults.- 71. Acute Myeloid Leukemia in Children.- 72. Acute Lymphoblastic Leukemia in Adults.- 73. Acute Lymphoblastic Leukemia in Children and Adolescents.- 74. Myelodysplastic Neoplasms/Syndromes (MDS).- 75. Allogeneic hematopoietic cell transplantation in pediatric MDS including refractory cytopenia of childhood and in juvenile myelomonocytic leukemia .- 76. Myelodysplastic/Myeloproliferative Neoplasms.- 77. Myelopro